GRAL GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individ…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run. A positive FDA vote is driving the recent surge in the multi-cancer early detection (MCED) test company. | ||
 Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next. Grail stock has catapulted, reaching a record high, as the FDA mulls its contender in the multibillion-dollar cancer detection market. | ||
 Here's Why Grail Stock Surged 55% This Week The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri. | ||
 MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%. | ||
 GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued? GRAIL (GRAL) is back in focus after the FDA's Medical Devices Advisory Committee backed its Galleri multi cancer early detection test, shortly after strong PATHFINDER 2 data in Nature Medicine reinforced its real world performance. That regulatory drumbeat has shown up quickly in the chart. GRAIL’s share price has climbed sharply in recent weeks, with a 7 day share price return of 35.73% and a 90 day share price return of 64.62%. The 1 year total shareholder return of 124.87% points to strong... | ||
 Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test Grail stock surged Thursday after a panel of advisors to the FDA backed the company's cancer-detecting blood test. | ||
 Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers. Dow Jones futures fell early Thursday, along with S&P 500 futures and especially Nasdaq futures. The 30-year Treasury yield hit a fresh long-term high while oil prices rose again. The Trump-Xi summit is on tap. | ||
 The Holy Grail In Cancer? FDA Panel Backs Blood Tests Grail stock was halted Wednesday after an Food and Drug Administration panel discussed the company's blood screening test for cancer. | ||
 GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why. Key TakeawaysFDA Signal: GRAIL stock jumped 34% on Monday after FDA staff found no major safety or accuracy issues with the Galleri cancer test. Street Gap: TIKR tracks 11 analysts on GRAL stock, split 5 buys and 6 holds, and their $79 mean target now sits 27% below Monday’s $108 close, a gap the Street hasn’t caught up to yet. | ||
 GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on Sept. 23 to discuss Grail’s application seeking approval of its cancer detection test. | ||
 Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday. | ||
 FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection. | ||
 Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 An insider sells 7,900 shares as the stock price has surged over the past year. | ||
 Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock. | ||
 GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices. Speaking at the Canaccord Genuity Growth Conference | ||
 GRAIL (GRAL) Q2 2026 Earnings Call Transcript Galleri volume jumped 35% year over year on physician adoption and digital partnerships. | ||
 Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? Why GRAIL Stock Is Back in Focus After the Galleri FDA Panel Date GRAIL (GRAL) is drawing fresh attention after regulators set a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. See our latest analysis for GRAIL. The Galleri panel date and recent Q2 update appear to have sharpened attention on GRAIL, with the share price up 9.59% over one day and 12.72% over 90 days. Over the same period, the... | ||
 Why BillionToOne Plummeted 38%, Leading A Medtech Sell-Off Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise. | ||
 GRAIL, Inc. Q2 2026 Earnings Call Summary Moby summary of GRAIL, Inc.'s Q2 2026 earnings call | ||
GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... GRAIL Inc (GRAL) reports 26% revenue growth and 35% increase in test volumes, while navigating FDA advisory committee timeline and competitive pressures. | ||
 GRAIL Q2 Earnings Call Highlights GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships. Revenue totaled $44.7 million in the second quarter, up 2 | ||
 Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates Jazz (JAZZ) delivered earnings and revenue surprises of -5.46% and +9.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70? The developer of blood-based cancer tests still has a bright future. | ||
 Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong. The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers. | ||